New P-CAB class drugs, K-CAB (tegoprazan) and Fexuclue (fexuprazan), for treating gastroesophageal reflux disease are competing for global entries.

HK inno.N’s K-CAB has entered 35 countries globally through technology exports or finished product exports. Within a year of its launch, Daewoong Pharmaceutical’s Fexuclue has been introduced to 24 countries, including Korea. Both companies are aiming to reach 1 trillion in sales.

K-CAB has expanded to 35 countries globally, and the company “Aims to achieve 1 trillion won in global sales”

HK inno.N announced on the 20th that K-CAB has recently received product approval from the Agencia Nacional de Medicamento